Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL

Status:
Terminated

Trial end date:
2007-05-01

Target enrollment:

Participant gender:

The purpose of the study is to evaluate the effects of increasing doses of CNF1010 on pharmacodynamic markers and hematological response.

Phase 1

Biogen